Starton Holdings Readies $40 Million IPO For Oncology Drug Treatments Development
Summarize this article with:
Donovan JonesInvesting Group LeaderFollow5ShareSavePlay(9min)CommentsSummaryStarton Holdings seeks a $40 million IPO to fund clinical-stage cancer drug reformulation and delivery system programs.STA's lead candidate, STAR-LLD, repurposes generic Revlimid via new delivery modalities, targeting multiple myeloma and lymphomas.The company lacks major institutional life science investors, is thinly capitalized, and holds no proprietary drug IP beyond delivery methods.My outlook is to sell (avoid) the IPO due to a weak competitive moat, limited backing, and poor historical returns for similar strategies. Catalin Rusnac/iStock via Getty Images A Quick Take On Starton Starton Holdings, Inc. (STA) has filed to raise $40 million in an IPO of its common stock, according to SEC S-1 registration information. The firm is a clinical-stage biopharmaThis article was written byDonovan Jones21.46K FollowersFollowDonovan Jones is an IPO research specialist with 15 years of experience identifying opportunities for high quality IPOs.He also leads the investing group IPO Edge, which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates. Learn moreAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.